Table 1

Baseline characteristics of patients with psoriatic arthritis in the intervention and control groups

Intervention
(N=30)
Control
(N=31)
Demographics/medication
 Age, years, mean (SD)50.5 (11.1)44.9 (12.1)
 Female, n (%)21 (70)20 (65)
 Disease duration, years, median (p25, p75)6 (2–12)4 (2–11)
 Synthetic DMARDs, n (%)28 (93)25 (81)
 Biologic DMARDs, n (%)11 (37)9 (29)
 Antihypertensive, n (%)4 (13)4 (13)
 Statins, n (%)3 (10)0 (0)
Cardiovascular assessment
 Current smoker, n (%)6 (20)4 (13)
 VO2max (mL/kg/min), mean (SD)28.73 (6.41)30.75 (7.95)
 Resting HR (beats/min), mean (SD)65.3 (11.5)66.4 (9.5)
 Systolic BP (mm Hg), mean (SD)124 (12)125 (16)
 Diastolic BP (mm Hg), mean (SD)77 (8)78 (11)
 Cholesterol (mmol/L), mean (SD)5.2 (0.8)5.1 (1.0)
 Triglyceride (mmol/L), median (p25, p75)1.1 (0.8–1.9)1.0 (0.7–1.4)
 LDL (mmol/L), mean (SD)3.2 (0.8)3.3 (0.7)
Body composition
 BMI (kg/m2), mean (SD)28.6 (4.2)27.6 (4.4)
 Total fat%, mean (SD)40.3 (7.1)38.7 (7.7)
 Truncus fat%, mean (SD)43.7 (8.2)41.3 (8.7)
 Lean muscle mass (g), mean (SD)48 423 (10163)48 436 (12066)
 Waist circumference (cm), mean (SD)100.1 (10.5)96.0 (13.8)
Disease activity
 HS-CRP (g/L), median (p25, p75)1.56 (0.9–4.5)1.87 (0.86–4.74)
 DAS44, mean (SD)2.00 (0.79)1.94 (0.76)
 Swollen joints, median (p25, p75)0 (0–1)0 (0–2)
 Tender joints 66, median (p25, p75)5 (1–10)6 (1–10)
 PGA (VAS 0–100), mean (SD)38.4 (23.7)41.6 (20.8)
 MHAQ, median (p25, p75)0.32 (0–0.75)0.25 (0.13–0.63)
  • BMI, Body Mass Index; BP, blood pressure; DAS44, disease activity score of 44 joints; DMARD, disease-modifying antirheumatic drug; HR, heart rate; HS-CRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; MHAQ, Modified Health Assessment Questionnaire; PGA, patient global assessment; VAS, Visual Analogue Scale; VO2max, maximal oxygen uptake.